Loading clinical trials...

Extended Reality Behavioral Activation: An Intervention for Major Depressive Disorder | Clinical Trials | Clareo Health

COMPLETEDNA

Extended Reality Behavioral Activation: An Intervention for Major Depressive Disorder

NCT05525390•Stanford University

Summary

The primary aims of this study are to assess the feasibility, acceptability, and tolerability of using an immersive extended reality (XR) headset to engage in behavioral activation (BA) for individuals diagnosed with major depressive disorder (MDD). The secondary aim of this study is to explore the efficacy of using XR to enhance BA therapy in a clinical MDD population.

Detailed Description

This is a treatment development trial. Participants will be randomized to receive either XR-enhanced behavioral activation or traditional behavioral activation. All groups will follow a brief-BA protocol developed for primary care settings over a four-session, three-week treatment period.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patient must meet DSM V criteria for MDD
•Patient must be at least 18 years of age
•Patient must be English speaking

Exclusion Criteria

•Substance Use Disorders in past year
•Any psychosis or bipolar disorder
•Any seizure in the last 6 months or untreated epilepsy
•Current nonsuicidal self-injury or parasuicidal behavior
•Current suicidal urges and intent
•Changing psychotherapy treatment within four months of study entry
•Changing psychotropic medication(s) within two months of study entry

Locations (1)

Stanford University

Stanford, California, United States

Key Dates

Start Date

December 19, 2022

Primary Completion Date

July 24, 2023

Completion Date

July 24, 2023

Last Updated

September 22, 2025

Enrollment

ACTUAL participants

Conditions

Major Depressive DisorderMDDDepression

Interventions

Extended Reality-Enhanced Behavioral Activation

BEHAVIORAL

Traditional Behavioral Activation

BEHAVIORAL

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

NCT07115329

Major Depressive Disorder

View study

RECRUITINGNA

ACT Together: Implementing a Web-Based Program With Brief Coaching for Parents of Children With Disabilities in Pediatric Outpatient Clinics

NCT07360600

ParentsChildren With Disabilities+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 22, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Extended Reality Behavioral Activation: An Intervention for Major Depressive Disorder

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

ACT Together: Implementing a Web-Based Program With Brief Coaching for Parents of Children With Disabilities in Pediatric Outpatient Clinics

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Readiness and Progress in Emotion Regulation Therapy

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression